Genetic mutation test kit Plasma-SeqSensei™

for breast cancergeneticblood

Highly sensitive down to 0.06% mutant allele fractions Quantitative detection of six mutant molecules or more with 95% confidence Fast turnaround time of two days Convenient data analysis and reporting with IVD-certified software Plasma-SeqSensei™ (PSS) assays enable highly sensitive and quantitative detection of mutations in circulating tumour DNA (ctDNA) from the blood plasma of patients with breast cancer by utilising next-generation sequencing technology. PSS's short and standardised workflow delivers results within two days including the generation of easy-to-read reports using laptop-compatible Plasma-SeqSensei™ IVD Software. The kit covers key gene mutations such as AKT1, ERBB2, ESR1, KRAS, PIK3CA, and TP53 to detect established and emerging predictive markers, resistance mutations, and frequently occurring genetic alterations in breast cancer. PSS Breast Cancer IVD Kit is intended to support clinicians with: detecting minimal residual disease recurrence surveillance (neo-)adjuvant response monitoring PSS technology Confident mutant reporting To increase sensitivity and reduce error rates associated with sequencing, the PSS library preparation workflow employs SafeSEQ technology1. This technology assigns a unique identifier (UID) to each DNA molecule during the target selection step. UIDs help track and identify real mutations in samples and distinguish them from polymerase or sequencing errors. PSS detects 0.06% and higher mutant allele fractions (MAF) with 95% certainty in a background of 10,000 wild-type copies.